Kura Oncology, Inc.
KURA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $53,883 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $849 | $0 | $0 |
| Gross Profit | $53,883 | -$849 | $0 | $0 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $169,967 | $115,235 | $92,812 | $84,721 |
| G&A Expenses | $77,111 | $50,569 | $47,053 | $46,537 |
| SG&A Expenses | $77,111 | $50,569 | $47,053 | $46,537 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$849 | $0 | $0 |
| Operating Expenses | $247,078 | $164,955 | $139,865 | $131,258 |
| Operating Income | -$193,195 | -$165,804 | -$139,865 | -$131,258 |
| % Margin | -358.5% | – | – | – |
| Other Income/Exp. Net | $21,230 | $13,173 | $4,025 | $792 |
| Pre-Tax Income | -$171,965 | -$152,631 | -$135,840 | -$130,466 |
| Tax Expense | $2,018 | $0 | $0 | $0 |
| Net Income | -$173,983 | -$152,631 | -$135,840 | -$130,466 |
| % Margin | -322.9% | – | – | – |
| EPS | -2.02 | -2.08 | -2.03 | -1.97 |
| % Growth | 2.9% | -2.5% | -3% | – |
| EPS Diluted | -2.02 | -2.08 | -2.03 | -1.97 |
| Weighted Avg Shares Out | 86,161 | 73,229 | 66,990 | 66,352 |
| Weighted Avg Shares Out Dil | 86,161 | 73,229 | 66,990 | 66,352 |
| Supplemental Information | – | – | – | – |
| Interest Income | $22,849 | $14,722 | $4,254 | $1,206 |
| Interest Expense | $1,619 | $1,549 | $229 | $414 |
| Depreciation & Amortization | $848 | $849 | $759 | $558 |
| EBITDA | -$169,498 | -$150,233 | -$134,852 | -$129,494 |
| % Margin | -314.6% | – | – | – |